Amgen regulatory affairs director
Executive Summary
Former FDA Office of Cellular, Tissues & Gene Therapies Acting Director Philip Noguchi, MD, joins Amgen. Noguchi will be regulatory affairs director, responsible for the company's regulatory and clinical development policy. Also joining Amgen's Washington D.C. office is former Baxter VP-Government Affairs & Public Policy Jonathon Spear. Spear will be VP-public policy and will work to define strategic public policy options...
You may also be interested in...
CBER cell therapies office director
FDA names former Intronn COO Edward Otto, PhD, director of the Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies, effective Nov. 14. Deputy Director Joyce Frey-Vasconcells, PhD, has served as acting director of CBER's cell therapies office since May after Acting Director Phil Noguchi, MD, moved temporarily to the Office of Orphan Products Development. Noguchi left FDA at the end of August to join Amgen (1"The Pink Sheet" Sept. 27, 2004, In Brief)...
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: